Corient Private Wealth
OTLK icon

Corient Private Wealth’s Outlook Therapeutics OTLK Stock Holding History

Corient Private Wealth’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30,100
Closed -$6.2K – 3190
2026
Q1 		$6.2K Buy
+30,100
New +$13K ﹤0.01% 2807
2024
Q1 		– Sell
-2,700
Closed -$21.3K – 2340
2023
Q4 		$21.3K Hold
2,700
– – ﹤0.01% 2221
2023
Q3 		$11.9K Buy
2,700
+1,700
+170% +$37.6K ﹤0.01% 2119
2023
Q2 		$34.8K Sell
1,000
-1,450
-59% -$39.5K ﹤0.01% 2036
2023
Q1 		$53.4K Buy
2,450
+1,000
+69% +$22.4K ﹤0.01% 1934
2022
Q4 		$31.3K Buy
+1,450
New +$31.5K ﹤0.01% 1653

Other funds holding OTLK

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM

Corient Private Wealth's OTLK Position: Q2 2026 in Review

Corient Private Wealth sold out of Outlook Therapeutics (OTLK) in Q2 2026, closing a stake of 30,100 shares — an estimated $6.2K sold.

Corient Private Wealth first reported a position in OTLK in Q4 2022 and held it in 6 quarters. The position peaked at $53.4K in Q1 2023. 69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • Corient Private Wealth reported no remaining Outlook Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Corient Private Wealth sold 30,100 Outlook Therapeutics shares in Q2 2026, an estimated $6.2K.
  • Corient Private Wealth first reported a position in Outlook Therapeutics in Q4 2022 and held it in 6 quarters.
  • Corient Private Wealth's Outlook Therapeutics position peaked at $53.4K in Q1 2023.
  • 69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.